Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.49 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15973896 | 0.85 | LMNA (0.61) | LMNAAKR1B1AKR1A1ADAM17PDE7A | |
| SCHEMBL1970646 | 0.84 | LMNA (0.59) | LMNAAKR1B1AKR1A1ADAM17PDE7A | |
| SCHEMBL29019957 | 0.76 | LMNA (1.00) | LMNAAKR1B1ADAM17SMN1; SMN2NPSR1 | |
| SCHEMBL15974325 | 0.76 | LMNA (0.47) | LMNAAKR1B1PTGER3TNF | |
| SCHEMBL539101 | 0.76 | LMNA (0.74) | LMNAAKR1B1ADAM17SMN1; SMN2NPSR1 | |
| SCHEMBL15973908 | 0.75 | LMNA (0.46) | LMNAAKR1B1ADAM17PTGER3TNF | |
| SCHEMBL15972677 | 0.73 | LMNA (0.47) | LMNAAKR1B1SMN1; SMN2PTGER3TNF | |
| SCHEMBL29689012 | 0.70 | PTGER3 (0.40) | LMNAAKR1B1AKR1A1PTGER3TNF | |
| SCHEMBL542982 | 0.70 | KMT2A (0.49) | LMNAAKR1B1PTGER3 | |
| SCHEMBL20135216 | 0.70 | PTGER3 (0.40) | LMNAAKR1B1AKR1A1PTGER3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168667-B2 | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such | GALAPAGOS NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2026799-B1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | DART THERAPUTICS, LLC. | 2010-08-19 | — | — | US | disclosed |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | SASU, GALAPAGOS (FR) | 2010-03-11 | — | — | US | disclosed |
| EP-2026799-A2 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | Galapagos SAS (FR) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007137874-A2 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | NR5A1, AR, HSD17B7 | LMNA 4085/4885AKR1B1 56/4885AKR1A1 33/4885 |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | NR5A1, AR, HSD17B7 | LMNA 4071/4885AKR1B1 56/4885AKR1A1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.